Please select the option that best describes you:
Topics:
Head and Neck Cancers • Radiation Oncology
Do you recommend altered fractionation when using cetuximab with head and neck RT?
Since the Bonner trial only found a benefit to the combination of cetuximab with the concomitant boost arm, do you routinely recommend this fractionation?
Answer from: Radiation Oncologist at Academic Institution
The 5-year update of the randomized study of RT vs RT and cetuximab for HN cancer added additional factors related to better outcome in patients receiving cetuximab (in addition to the findings that only oropharyngeal cancer benefited, published previously in the NEJM paper). The additional factors...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
I think we have to, given it is cetuximab
Radiation Oncologist
For more information on altered fractionation and systemic therapy see reference below:Summary of major radiation fractionation and chemotherapy trials for organ preservation therapy in locally advanced head and neck squamous cell carcinoma. Parsons JT, Greene BD., Pract Radiat Oncol. 2015 Sep-Oct;5...
Answer from: Radiation Oncologist at Academic Institution
I agree with @Avraham Eisbruch's answer. No compelling evidence for hyperfractionation with CTXmab. And acute toxicity may be increased.